1. Introduction {#s1}
===============

Irritable bowel syndrome (IBS) is a chronic visceral pain disorder^[@R15],[@R16]^ of an incompletely understood pathophysiology, yet growing evidence supports the notion that altered brain-gut interactions may underlie symptoms and their persistence.^[@R44]^ Comorbid psychopathologies and maladaptive pain-coping strategies are common^[@R15],[@R59]^ and likely contribute to increased pain symptoms and emotional distress.^[@R59]^

In IBS, functional brain imaging studies consistently document alterations involving brain regions associated with emotion processing and modulation, particularly the anterior insula (aINS), a key node of the salience network.^[@R6],[@R12],[@R45]^ According to present models of insular function, interoceptive signals, including visceral pain, are received in the posterior insula and then processed in the aINS as a hub of interoceptive awareness, pain perception, and its cognitive and emotional modulation.^[@R6],[@R12],[@R49]^ Increasing evidence further supports a triple network model, in which the aINS plays a crucial role in switching between the task-positive executive control network and the task-negative default mode network.^[@R46],[@R61]^ These findings suggest that the aINS does not only represent a key part of the limbic system but also is a hub of cognitive control and a facilitator of visceral pain.

Despite these well-recognized functional aINS alterations in the pathophysiology of visceral pain, in IBS the underlying changes in brain chemistry are poorly understood. Quantitative magnetic resonance spectroscopy (qMRS) allows for the detection and quantification of major excitatory and inhibitory neurochemicals in the human brain, namely glutamate (Glu) and γ‐aminobutyric acid (GABA), respectively. Glutamate is routinely reported with its precursor glutamine (Gln) as a combined measure (Glx)^[@R55]^ and GABA is typically reported with coedited macromolecular signals as GABA+.^[@R52]^ There is growing evidence of aberrant insular brain neurochemistry in several chronic pain conditions. Research findings have shown increased Glx concentration in the aINS in chronic pelvic pain^[@R2]^ and both reduced GABA and elevated Glu concentrations in fibromyalgia.^[@R20],[@R27]^ In a study of patients with IBS, one qMRS study reported reduced hippocampal glutamatergic neurotransmission.^[@R51]^ Interestingly in this study, Glu concentrations in the left, but not right hippocampus of patients with IBS were negatively correlated with anxiety, pain catastrophizing, and pain duration, suggesting a lateralization on a biochemical level. Functional lateralization has also been observed for the aINS with the right insula being associated with sympathetic arousal, avoidance behavior, and energy expenditure, while the left insula seems to be related to parasympathetic activity, calm behavior, and energy nourishment.^[@R11],[@R12]^ However, little is known about a possible lateralization of aINS involvement in pain processing and pain modulation and its possible biochemical basis in patients with IBS.

The aim of this study was to investigate aINS glutamatergic and GABAergic neurotransmitter concentrations in patients with IBS compared with age-matched healthy controls (HC). We further explored the predictive value of abdominal pain as a cardinal IBS symptom, as well as psychological factors relevant to IBS, such as anxiety, depression, and maladaptive pain-coping strategies, for concentrations of aINS neurotransmitters. Thus, this study focused on the question of whether or not neurotransmitter alterations and associations with disease-related or psychological measures would be left or right lateralized or show shared characteristics across hemispheres.

2. Methods {#s2}
==========

2.1. Study participants {#s2-1}
-----------------------

Thirty-nine women with IBS, mean age 32.1 years (range 18-57 years) who met the Rome III criteria were recruited from the Gastroenterology Department, University Hospital in Linköping, Sweden. Twenty-one age-matched healthy women, mean age 32.1 years (range 20-55 years), without a medical history of gastrointestinal symptoms or complaints were recruited by local advertisement. The exclusion criteria for both groups were organic gastrointestinal disease, metabolic, neurological, or severe psychiatric disorders, nicotine intake within 2 months before the study, ferromagnetic implants, claustrophobia, and large tattoos. All participants were right-handed. Previous diagnoses of anxiety and/or depression in patients were extracted from their medical history documentation.

The regional ethical review board in Linköping approved the study (Dnrs. 2013/506-32; 2014/264-32). All subjects gave their written informed consent in accordance with the Helsinki Declaration.

2.2. Magnetic resonance imaging data acquisition and analysis {#s2-2}
-------------------------------------------------------------

Participants were requested to fast for at least 4 hours (water was acceptable) and refrain from consuming alcohol and taking any IBS-related pain or sleep medications for at least 24 hours before the MR examination. Magnetic resonance data were collected on a 3 T Philips Ingenia (Philips Healthcare, Best, the Netherlands) equipped with a 32-channel head coil at the Center for Medical Image Science and Visualization (CMIV) at Linköping University, Sweden. Initially, T1-weighted 3D FFE images were acquired in all participants to exclude brain abnormalities and to ensure accurate voxel placement for subsequent spectroscopy measurements using the following parameters: inversion preparation and delay 900 ms, SAG-plane, FOV 256 × 240 × 170 mm^3^, resolution 1 × 1 × 1 mm^3^, flip angle 9°, TR 7 ms, TE 3.2 ms, TA 5:34. Subsequently, qMRS measures of the left and right aINS were accomplished using a MEGA-PRESS sequence^[@R47],[@R48]^ (kindly provided by R.Edden, Johns Hopkins University) with the following parameters: TR/TE = 2000/68 ms, edited pulses ON at 1.90 ppm, edited pulses OFF at 7.46 ppm, water suppression MOIST, 40 dynamics in a voxel of 4.5 × 2.0 × 3.0 cm^3^ placed in the right and left aINS, respectively (Figs. [1](#F1){ref-type="fig"}A and B). In addition, a 2-dynamic unsuppressed water reference measurement was collected to obtain a reference of water in the tissue within the voxel. The MRS voxel was defined based on the parcellation in the Harvard-Oxford cortical structural atlas^[@R14],[@R22],[@R24],[@R43]^ (<https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases>) and was positioned based on individual high-resolution structural scans by an experienced radiographer specialized in magnetic resonance imaging (MRI)/MRS acquisition following a standardized protocol. Data were phase-corrected^[@R34]^ and frequency-aligned based on the water residual in the suppressed data. A difference spectrum was computed by subtracting the average OFF spectrum from the average ON spectrum and used as input to LCModel^[@R53]^ (Version 6.3-1L) to compute GABA+ concentrations (Fig. [1](#F1){ref-type="fig"}C). OFF dynamics were analyzed to assess concentrations of Glx (Fig. [1](#F1){ref-type="fig"}D). Concentrations were water-scaled using the water reference, resulting in concentrations with absolute units of mM. Data are provided with no correction for the contribution of cerebrospinal fluid.

![Typical qMRS volume of interest (voxel size 4.5 × 2.0 × 3.0 cm^3^) placement in the (A) right and (B) left aINS. The yellow box illustrates the voxel targeting the GABA signal at 3.0 ppm, and the white box illustrates the voxel the water residual at 4.7 ppm originates from, which shows the chemical shift displacement. Representative spectra with LCModel fitting depict (C) an averaged difference spectrum for the extraction of GABA+ and (D) an averaged MEGA-PRESS OFF spectrum for Glx extraction (labeled as 2 and 7, extracted solely from OFF-spectra) from a healthy volunteer (black line: postprocessed spectra before fitting; red line: LCModel fit). Residuals are shown at the top of each panel. (Assignments: 1, creatine (-2CH2-); 2, Glx (-2CH-); 3, choline (-N(CH3)3); 4, creatine (-N(CH3)); 5, GABA+ (-4CH2-); 6, tNA (-3CH2-); 7, Glx (-4CH2-); 8, GABA+ (-2CH2-); 9, tNA (-2CH3); 10, GABA+ (-3CH2-); 11 to 13, macromolecules and lipids, -CH2-).^[@R25]^ aINS, anterior insula; Glx, glutamate+glutamine; GABA+, γ-Aminobutyric acid + coedited macromolecular signals; qMRS, quantitative magnetic resonance spectroscopy; tNA, total N-Acetyl compounds (NAA + NAAG).](jop-160-2004-g001){#F1}

2.3. Questionnaires and symptom diary {#s2-3}
-------------------------------------

Questionnaire data from all participants were collected for sample characterization and for the assessment of IBS-related and psychological variables. In addition, data extracted from symptom diaries were obtained from the patients with IBS, as described below.

### 2.3.1. Irritable bowel syndrome severity scoring system (IBS-SSS) {#s2-3-1}

Irritable bowel syndrome severity scoring system is a 5-item questionnaire evaluating overall IBS symptom severity by assessing the frequency and the intensity of abdominal pain and distension, the satisfaction with bowel habits, and interference with daily life.^[@R21]^ Each item generates a score between 0 and 100 with a maximal sum score of 500. Sum scores indicate mild (75-175), moderate (175-300), or severe (\>300) disease.

### 2.3.2. Visceral sensitivity index (VSI) {#s2-3-2}

Visceral sensitivity index was implemented to assess gastrointestinal symptom-specific anxiety.^[@R36]^ The 15-item self-report questionnaire evaluates cognitive, emotional, and behavioral responses to fear of gastrointestinal sensations, symptoms, and the context in which the symptoms are experienced. Items are scored on a reversed 6-point scale ranging from 0 to 5, with sum scores between 0 and 75. Higher scores indicate more severe symptom-specific anxiety.

### 2.3.3. Hospital anxiety and depression scale (HADS) {#s2-3-3}

The hospital anxiety and depression scale was used to measure symptoms of depression and anxiety.^[@R71]^ The tool consists of 7 items for a depression (HADS-D) and an anxiety subscale (HADS-A), respectively, with scores on each subscale ranging from 0 to 21. Cutoff values are indicated as ≥8 for subclinical (suspicious) anxiety or depression and ≥11 as definite cases on both the HADS-D and HADS-A, respectively.^[@R5]^

### 2.3.4. Coping strategies questionnaire (CSQ) {#s2-3-4}

The coping strategies questionnaire was used to evaluate cognitive and behavioral strategies to cope with pain,^[@R56]^ involving 6 subscales for cognitive strategies (ignoring pain, reinterpreting pain, diverting attention, calming self-statements, catastrophizing, and praying/hoping) and 2 subscales for behavioral strategies (increasing activity and increasing pain behavior). Sum scores between 0 and 36 for each subscale indicate how frequently a coping strategy is used.

### 2.3.5. Patient health questionnaire (PHQ-15) {#s2-3-5}

The PHQ-15 was used to assess the somatic symptom severity across 15 different somatic symptoms.^[@R35]^ Sum scores ranging from 0 to 30 indicate severity of somatic symptoms.

### 2.3.6. Brief pain inventory (BPI) {#s2-3-6}

The brief pain inventory is a validated pain assessment tool measuring both the intensity of pain (4 items, sensory dimension) and interference of pain with the patient\'s life (7 items, reactive dimension).^[@R8]^ Each item is scored on a 0 to 10 scale with sum scores ranging from 0 to 40 for pain severity and from 0 to 70 for interference and higher scores indicating higher levels of pain severity and interferences, respectively.

### 2.3.7. MacArthur scale of subjective social status (SES ladder) {#s2-3-7}

All participants completed the MacArthur Scale of Subjective Social Status to assess the common sense of the individual\'s social status, which has been shown to be tightly linked to psychological functioning and health status.^[@R1],[@R60]^ Using a symbolic stepladder image, the tool provides a score between 0 and 10 as a summative measure of the subjective social status.

### 2.3.8. Gastrointestinal symptom diary (GSD) {#s2-3-8}

Patients with IBS recorded their gastrointestinal symptoms on 14 consecutive days using validated diary cards^[@R54]^ (Supplementary Fig. 1, available at <http://links.lww.com/PAIN/A788>). The symptoms (abdominal pain, nausea, and bloating) as well as every single bowel movement and stool consistency (defined by the Bristol Stool Chart^[@R39]^) were reported along a 24-hour time axis. The values were manually scored, and the mean frequency of symptom episodes per week and symptom duration per day was extracted from the diary data.

2.4. Statistical analyses {#s2-4}
-------------------------

Statistical analyses were performed using SPSS version 25 (IBM Corporation, Armonk, NY) and GraphPad Prism 7 (<https://www.graphpad.com/scientific-software/prism>). As not all measures passed the Shapiro--Wilk normality test, the Mann--Whitney *U* test was used to address group comparisons in Glx and GABA+ concentrations and questionnaire data. χ^2^ test was used for group comparisons of medical journal data regarding previously diagnosed anxiety and/or depression and medication use. In a second step, multiple linear regression analyses using a stepwise approach (criteria: probability to enter ≤0.05, probability to remove ≥0.10) were conducted in patients with IBS to explore whether IBS-related measures (particularly pain reports) and psychological factors significantly predicted concentrations of aINS Glx and GABA+, respectively. Statistical significance was set at *P* \< 0.05. Results are reported as median and interquartile range, unless indicated otherwise, and effect sizes are given as Cohen\'s d for results from *U* test and as Cramer\'s V for χ^2^ test.

3. Results {#s3}
==========

3.1. Clinical characteristics {#s3-1}
-----------------------------

Results of sociodemographic and clinical characteristics are given in Table [1](#T1){ref-type="table"}. There was no significant difference in age between the groups. Women with IBS displayed significantly lower socioeconomic status in comparison with healthy women. Based on medical history documentation, 13 patients with IBS were previously diagnosed with anxiety and/or depression as a frequent comorbidity in IBS. Sixteen patients were on stable doses of IBS-related pain treatment with neuromodulators, in line with current recommendations.^[@R62]^ Results of the Mann--Whitney *U* test comparing IBS and HC groups with respect to IBS-related and psychological variables are given in Table [2](#T2){ref-type="table"}. As expected, patients with IBS showed significantly higher IBS and somatic symptom severity, pain intensity, and interference, and reported increased severity of anxiety, depression, and gastrointestinal symptom-specific anxiety. Patients also reported a significantly higher tendency to use maladaptive pain-coping strategies, ie, they more frequently showed a catastrophizing coping style and less frequently ignored pain. No other differences in pain-coping strategies as assessed with the coping strategies questionnaire were detected.

###### 

Sociodemographic and clinical characteristics of patients with IBS and healthy controls.

![](jop-160-2004-g002)

###### 

Characterization of patients with IBS and healthy controls with respect to disease-related and psychological measures.

![](jop-160-2004-g003)

Thirty-three patients filled in the Gastrointestinal Symptom Diary cards. Data from 6 patients were not available due to poor compliance. Descriptive statistics of the extracted values are presented in Table [3](#T3){ref-type="table"}. On average, patients with IBS reported 7 episodes of abdominal pain per week with a mean of more than 3 hours of daily pain duration. Abdominal distension was reported as frequently and persisting longer, whereas nausea was less frequent.

###### 

Gastrointestinal symptom diary data collected in the IBS sample.

![](jop-160-2004-g004)

3.2. Group differences in anterior insula neurotransmitter levels {#s3-2}
-----------------------------------------------------------------

Analyses of qMRS data revealed significant group differences in aINS neurotransmitter concentrations when comparing patients with IBS and HC. Specifically, patients showed significantly reduced concentrations of Glx in aINS bilaterally with more pronounced effects for the right hemisphere (left aINS U = 228.5; *P* = 0.017, right aINS U = 170; *P* \< 0.001; Fig. [2](#F2){ref-type="fig"} A and B). GABA+ concentrations in aINS did not significantly differ between groups (Fig. [3](#F3){ref-type="fig"} A and B).

![Results from group comparisons of Glx concentrations in (A) left and (B) right aINS in HC and patients with IBS. All data are given as median and interquartile range (IQR). Significantly lower bilateral aINS Glx concentrations were observed in patients with IBS compared to HC. \**P* \< 0.05; \*\*\**P* \< 0.001. aINS, anterior insula; HC, healthy controls; IBS, irritable bowel syndrome.](jop-160-2004-g005){#F2}

![Results from group comparisons of GABA+ concentrations in (A) left and (B) right aINS between HC and patients with IBS. All data are given as median and interquartile range (IQR). No significant group differences were detected for GABA+ in either hemisphere. aINS, anterior insula; HC, healthy controls; IBS, irritable bowel syndrome.](jop-160-2004-g006){#F3}

3.3. Regression analyses {#s3-3}
------------------------

Stepwise regression analyses conducted in patients with IBS revealed hemisphere-specific predictors of Glx concentrations. Specifically, abdominal pain duration as assessed by gastrointestinal symptom diaries significantly predicted right aINS Glx concentrations (*R*^2^ = 0.354; F = 15.32; *P* = 0.001). In addition, a model including pain behaviors as a coping strategy was identified (*R*^2^ = 0.117; F = 5.99; *P* = 0.021). A longer pain duration per day (ß = −0.624; t = −4.44; *P* \< 0.001; Fig. [4](#F4){ref-type="fig"}A) and less frequently used pain behaviors to cope with pain (ß = 0.344; t = 2.45; *P* = 0.021; Fig. [4](#F4){ref-type="fig"}B) independently predicted lower Glx concentrations.

![Scatterplots with regression curves and 95% confidence intervals depicting significant results from stepwise regression: (A) abdominal pain duration and (B) pain behaviors as predictors of Glx concentration in the right aINS, (C) diverting attention as a predictor of left aINS Glx and (D) calming self-statements as a significant predictor of GABA+ concentrations in the left aINS. aINS, anterior insula.](jop-160-2004-g007){#F4}

For the left hemisphere, diverting attention (an adaptive pain-coping strategy) significantly explained variance in aINS Glx concentrations (*R*^2^ = 0.228; F = 8.28; *P* = 0.008). Here, lower Glx in left aINS was significantly predicted by less frequent use of the adaptive coping style (ß = 0.478; t = 2.88; *P* = 0.008; Fig. [4](#F4){ref-type="fig"}C). Regarding GABA+ concentrations, regression analyses for the left hemisphere identified calming self-statements as an adaptive pain-coping strategy to be a significant predictor (*R*^2^ = 0.187; F = 6.46; *P* = 0.017), with a lower tendency to use the adaptive coping style predicting higher concentrations of the inhibitory neurotransmitter (ß = −0.433; t = −2.54; *P* = 0.017; Fig. [4](#F4){ref-type="fig"}D). No predictor for concentrations of right aINS GABA+ was found.

4. Discussion {#s4}
=============

Our study examined aINS neurotransmitter levels in women with IBS, a mechanism that might contribute to aberrant insular function consistently observed in chronic visceral pain disorders.^[@R3],[@R7],[@R9],[@R19],[@R32],[@R38],[@R50]^ We observed decreased concentrations of the excitatory neurotransmitter Glx in bilateral aINS in women with IBS compared with healthy women, whereas no significant group differences were found in aINS GABA+ concentrations. Furthermore, we demonstrated that longer duration of pain predicted lower Glx concentrations in the right aINS while lower Glx concentrations in the left aINS were predicted by less use of adaptive pain-coping strategies.

The aINS is considered a key node of interoceptive awareness with crucial relevance to pain processing and modulation.^[@R10],[@R12],[@R13],[@R58]^ It is structurally and functionally connected with the limbic system^[@R41]^ and other regions involved in emotion processing and regulation,^[@R66]^ supporting a central role of aINS particularly in emotional aspects of pain. As a core region of the brain\'s salience network, the aINS further seems to be involved in switching between the default mode network and the central executive network in the face of salient events^[@R46],[@R61]^ and serves an integrative function in the context of pain.^[@R4]^ The region is therefore likely of particular relevance in adaptive attentional, cognitive, and emotional responses to pain. Extensive reorganization of insular connectivity within the salience, default mode, and central executive networks^[@R29],[@R31],[@R65]^ has previously been described in patients with IBS, further supporting the assumption of substantial alterations within pain- and emotion-regulatory networks in IBS. Reduced Glx concentrations in bilateral aINS, as observed herein, could therefore reflect dysfunctional excitatory neurotransmission that might contribute to compromised regulatory attentional, cognitive, and emotional pain-related processing in patients suffering from IBS. At the same time, given extensive projections of aINS also to brainstem regions associated with descending pain modulation,^[@R63]^ reduced excitation of aINS could further detrimentally affect communication pathways with descending pain inhibitory circuits, as supported by findings also from other chronic pain conditions,^[@R58],[@R64],[@R68]^ and thereby impact the perception of pain.

In support of our spectroscopic findings, reduced hippocampal Glu concentrations in patients have previously been reported in the only other existing MRS study conducted in IBS.^[@R51]^ Studies in other chronic pain conditions highly comorbid with IBS, however, revealed partly inconsistent results, such as unaltered aINS neurochemistry in fibromyalgia,^[@R17],[@R18],[@R27],[@R28]^ or increased Glu concentrations in posterior insula in this disease group.^[@R27]^ Finally, As-Sanie et al.^[@R2]^ demonstrated increased aINS Glx concentrations in women with endometriosis-associated chronic pelvic pain in comparison with healthy participants. While these inconsistent findings might be due to methodological differences, they could also indicate disease-specific neurochemical alterations, possibly adding to the chemical heterogeneity of the living human brain, as previously described.^[@R26],[@R29],[@R30],[@R52]^

Interestingly, excitatory neurotransmitter concentrations in patients seemed to show hemisphere-specific relations to abdominal pain and pain‐coping, providing novel evidence on a biochemical level to support a functional asymmetry of aINS.^[@R10],[@R12],[@R69]^ Specifically, abdominal pain duration experienced by women with IBS was the most substantial predictor of lower Glx concentrations in the right but was not associated with Glx levels in the left aINS. The right aINS is considered to contain representation of sympathetic afferent stimuli such as pain and temperature.^[@R11]^ Accordingly, Zhou et al. demonstrated a positive correlation between spontaneous neural activity in the right INS and disease severity in functional dyspepsia,^[@R70]^ which is a visceral pain disorder known to overlap with IBS in up to 50% of patients.^[@R67]^ In IBS, successful treatment (hypnotherapy and educational intervention) was not only associated with a significant improvement in symptom severity, but also led to a significant attenuation in right aINS activation during rectal distensions.^[@R40]^ Our findings extend these observations of a distinct association between pain perception and right insular function in visceral pain conditions to a biochemical level.

We further found reduced left, but not right, aINS excitatory neurochemistry to be related to less use of adaptive cognitive coping strategies, specifically diverting attention when confronted with pain. Adaptive pain-coping strategies are considered as behavioral contributors to an effective top-down modulation of pain. Also, a stronger involvement of left rather than right aINS in top-down behavioral modulation has recently been proposed.^[@R33]^ Moreover, Zautra et al.^[@R69]^ showed that activating the left aINS by increased parasympathetic input (slow breathing) was correlated with decreases in affective responses to acute pain stimulation in healthy volunteers, whereas this regulatory mechanism appeared to be blunted in patients with fibromyalgia. Our findings complement and extend this evidence of a specific role of left aINS in adaptive top-down pain modulation, suggesting that reduced excitatory neurotransmitter levels in IBS might contribute to alterations involving a compromised capability to adaptively cope with pain.

Taken together, the observed pattern of increased pain associated with lower Glx concentrations in right aINS and less use of adaptive cognitive coping related to lower left insular Glx concentrations provide novel biochemical evidence suggesting an asymmetry of insular function of putative relevance in pain processing and its cognitive regulation in IBS.

In a heterogeneous group of conditions such as IBS, our study has several strengths. First, a recall bias is known to be an inherent problem of retrospective reports.^[@R37]^ The prospective pain data collection from gastrointestinal diaries applied in this study therefore likely provides a more reliable measure of symptoms in patients. Second, our study included well-phenotyped and age-matched samples of women with IBS and healthy women. Given that brain chemistry is reportedly sex- and age-dependent,^[@R26],[@R29],[@R30],[@R52]^ together with the rationale that IBS is a disease with female predominance,^[@R15],[@R16]^ including only women strengthens the study results. However, this approach might at the same time limit generalizability of this study; therefore, follow-up studies on insular neurotransmission are needed to address biochemical changes also in men suffering from IBS and to allow for the investigation of possible, yet unknown sex differences in insular biochemistry.

Furthermore, the current study has some limitations with respect to the spectroscopy measurements applied, which need to be addressed. The region of investigation in spectroscopic measures involves different tissue types, such as gray matter, white matter, and cerebrospinal fluid. The current data were not corrected for possibly different contribution of these tissue types. While we therefore cannot exclude that group differences observed in Glx concentrations may have been affected by distinct features in tissue contribution in women with IBS and healthy women, a recent report using high-resolution MRI demonstrated differences in concentrations of GABA to be substantially larger when comparing gray matter and white matter than was the case for Glu.^[@R23]^ Given that, even using a sequence optimized for GABA, no group differences in concentrations of the inhibitory neurotransmitter were observed, our findings are unlikely to be mainly attributable to differences in tissue contribution.

Finally, the MEGA-PRESS technique used in this study is considered "state of the art" for a noninvasive evaluation of GABA concentrations.^[@R52],[@R57]^ While assessing Glx from MEGA-PRESS "OFF" spectra represents a good proxy for conventional measures of Glx concentrations in brain tissue,^[@R42],[@R53]^ the sequence is primarily optimized for the detection of GABA. Specifically, since the echo time used in the editing sequence in this study was chosen for optimal GABA+ quantification, this may have led to a loss in signal-to-noise ratio of Glx due to the faster relaxation of Glu compared with GABA. Further research focusing on the excitatory neurotransmitter and applying an acquisition protocol optimized for the detection of Glu are needed to substantiate the reported observations.

Together, our findings of decreased glutamatergic yet unaltered GABAergic neurotransmitter concentrations in patients with IBS and left and right lateralized associations with abdominal pain and coping provide novel insights into brain molecular mechanisms potentially contributing to IBS pathophysiology by affecting circuits of salience and pain modulation. Our observations support the assumption that glutamatergic deficiency might be involved in a failure to adaptively engage aINS in pain processing and modulation, which could contribute to more pain symptoms and increased symptom burden in patients with IBS.
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